ARMATA PHARMACEUTICALS, INC. financials

ARMP CIK 0000921114

Source: EDGAR filings · Built 2026-06-02T02:21:55Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -26.30M -39.43M -55.57M -34.69M -24.88M -19.09M
EBITDA -35.10M -41.11M -39.92M -36.05M -22.65M -20.47M
Working Capital 1.72M -36.94M 2.69M 2.17M 10.18M 4.14M
Net Debt 176.27M 55.73M 83.17M 33.96M 27.70M 2.78M
Return on Equity (ROE) 79.51% 39.39% 215.33% -102.32% -91.17% -117.63%
Return on Assets (ROA) -226.06% -21.88% -70.19% -38.52% -33.19% -56.13%
Current Ratio 1.19× 0.23× 1.16× 1.09× 3.11× 1.62×
Debt-to-Equity -0.85× -1.35× -3.02× 1.35× 1.50× 0.66×
Cash Conversion Ratio 0.15× 1.99× 0.69× 0.88× 1.02× 0.82×
Accruals Ratio -1.93× 0.22× -0.22× -0.05× 0.01× -0.10×
CapEx Coverage -47.53× -19.98× -5.82× -14.69× -18.08× -22.17×
Free Cash Flow Per Share $-0.73 $-0.67 $-1.54 $-1.01 $-1.03 $-1.16

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/B 1.24× 5.85× 2.95×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 41.54M 47.61M 45.42M 42.45M 28.30M 22.41M
Operating Income (Loss) -36.63M -42.44M -40.89M -36.95M -23.82M -21.59M
Net Income (Loss) Attributable to Parent -173.80M -18.92M -69.05M -36.92M -23.16M -22.18M
Earnings Per Share, Basic $-4.80 $-0.52 $-1.91 $-1.08 $-0.96 $-1.35
Weighted Average Number of Shares Outstanding, Basic 36.24M 36.16M 36.08M 34.29M 24.10M 16.42M
Earnings Per Share, Diluted $-4.80 $-0.89 $-1.91 $-1.08 $-0.96 $-1.35
Weighted Average Number of Shares Outstanding, Diluted 36.24M 59.06M 36.08M 34.29M 24.10M 16.42M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 8.69M 9.29M 13.52M 14.85M 10.29M 9.65M
Assets, Current 10.67M 11.31M 19.15M 27.05M 14.99M 10.85M
Assets 76.88M 86.44M 98.36M 95.83M 69.77M 39.52M
Liabilities, Current 8.95M 48.25M 16.46M 24.87M 4.81M 6.71M
Liabilities 295.48M 134.46M 130.43M 59.75M 44.37M 20.66M
Stockholders' Equity Attributable to Parent -218.60M -48.02M -32.06M 36.08M 25.40M 18.86M
Common Stock, Shares, Outstanding 36.43M 36.18M 36.12M 36.14M 27.11M 18.69M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -25.76M -37.55M -47.42M -32.48M -23.57M -18.27M
Payments to Acquire Property, Plant, and Equipment 542.00K 1.88M 8.14M 2.21M 1.30M 824.00K
Net Cash Provided by (Used in) Investing Activities -542.00K -1.88M -8.13M -2.21M -1.30M -824.00K
Net Cash Provided by (Used in) Financing Activities 25.61M 34.96M 53.99M 44.02M 25.52M 23.21M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ARMP CIK 0000921114), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SANM

Sanmina Corporation

BHRB

Burke & Herbert Financial Services Corp.

IMXI

INTERNATIONAL MONEY EXPRESS, INC.